Hyderabad, August 07, 2014 –
Aurobindo Pharma Ltd will be ramping up its generic business in the western European markets. It had acquired about 1,250 dossiers as part of its strategy to expand in the region and some more new products were likely to be launched in the current financial year, its Chief Executive Officer – Formulations, Arvind Vasudeva, said in his statement in the annual report 2013-14 released here on Monday. In addition, there were about 100 products already exported from the manufacturing units in India. Aurobindo would leverage on its large scale manufacturing capabilities in India apart from the existing European infrastructure, he added.
